Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

ABSTRACT: The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.

DISEASE(S): Kidney Neoplasms,Breast Neoplasm,Lung Neoplasm,Ovarian Neoplasm,Ovarian Neoplasms,Renal Neoplasm,Pancreatic Neoplasms,Breast Neoplasms,Lung Neoplasms,Pancreatic Neoplasm,Neoplasms,Cancer

PROVIDER: 2007413 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR